---
agent_readiness:
  band: human-only
  dimensions:
    agent_card: false
    agent_skills: false
    agentic_access: false
    auth_clarity: false
    consent_identity: false
    dry_run_mode: false
    error_semantics: false
    event_surface_described: false
    idempotency: false
    mcp_server: false
    openapi_examples: false
    rate_limit_signal: false
    spec_presence: false
    well_known_catalog: false
  schema_version: 0.2
  score: 0.0
  scored_at: '2026-08-17'
api_count: 0
artifact_total: 1
common:
- group: auth
  title: ''
  type: DomainSecurity
  url: security/attovia-domain-security.yml
- group: agent
  title: ''
  type: LLMsTxt
  url: llms/attovia-llms.txt
- group: company
  title: ''
  type: Website
  url: https://www.attovia.com/
- group: commercial
  title: ''
  type: TermsOfService
  url: https://www.attovia.com/terms-of-use/
- group: commercial
  title: ''
  type: PrivacyPolicy
  url: https://www.attovia.com/privacy-policy/
- group: operate
  title: ''
  type: Support
  url: https://www.attovia.com/contact-us/
- group: other
  title: ''
  type: SecondaryMarket
  url: https://forgeglobal.com/attovia_stock/
coverage:
  checked: '2026-08-06'
  detail: Attovia is a clinical-stage biopharmaceutical company whose product is multispecific antibody therapeutics, not software — its entire public web presence is a ten-page WordPress corporate site (platform, pipeline, team, careers, contact, legal) with no developer section, and api/developers/developer/docs.attovia.com do not resolve in DNS.
  evidence:
  - status: 404
    url: https://www.attovia.com/openapi.json
  - status: 404
    url: https://www.attovia.com/.well-known/agent-card.json
  - status: 404
    url: https://www.attovia.com/llms.txt
  - status: 200
    url: https://www.attovia.com/page-sitemap.xml
  reason: not-a-software-company
  state: none
created: '2026-08-06'
description: Attovia Therapeutics is a clinical-stage biopharmaceutical company in San Carlos, California, founded in 2022 and developing next-generation precision biologics for immune-mediated diseases. Its proprietary ATTOBODY platform is a modular protein design technology built on biparatopic nanobody scaffolds, used to engineer multispecific biologics that inhibit two, three, or four disease-driving pathways from a single molecule while targeting improved selectivity, stability, and less frequent dosing than existing therapies. The lead program ATTO-1310 is an anti-IL-31 candidate in Phase 1 for chronic pruritus and high-itch atopic dermatitis; ATTO-2306 (IL-31 x IL-13) and ATTO-1091 (TL1A x IL-23p19 x integrin alpha-4-beta-7, for inflammatory bowel disease) are in IND-enabling studies, alongside discovery-stage programs in rheumatology, IBD, and respiratory disease. The company raised a $105M Series B led by Goldman Sachs Alternatives and listed on Nasdaq as ATTO in August 2026, raising
  $289M. Attovia publishes no public API, developer portal, SDK, or machine-readable specification — its product is therapeutics, not software.
image: https://www.attovia.com/wp-content/uploads/2023/09/Attovia-logo.svg
layout: provider
modified: '2026-08-06'
name: Attovia Therapeutics
nav: Providers
network: true
overview: 'Attovia Therapeutics is profiled on the [APIs.io](https://apis.io/) network. Tagged areas include Company, Biotechnology, Biopharmaceutical, Life Sciences, and Immunology.


  Attovia Therapeutics'' developer surface includes support and 6 more developer resources.'
random_paper: 15
score:
  band: minimal
  composite: 11.8
  delta: 0.0
  facets:
    commercial_clarity: 21.1
    contract_quality: 0.0
    developer_ergonomics: 4.3
    discoverability: 57.4
    governance: 0.0
    operational_transparency: 0.0
  previous_composite: 11.8
  regulatory:
    applies: true
    matched_via: tags
    regime: Health
    regime_id: health
    score: 17.5
  schema_version: 0.11.0
  scored_at: '2026-08-17'
  trend: flat
screenshot: https://raw.githubusercontent.com/api-evangelist/attovia/refs/heads/main/screenshots/attovia-2026-08-07T161912.png
security:
- kind: domain-security
  name: Attovia Domain Security
  slug: attovia-domain-security
  summary_line: TLSv1.3 · HSTS · DMARC
slug: attovia
tags:
- Company
- Biotechnology
- Biopharmaceutical
- Life Sciences
- Immunology
- Therapeutics
- Drug Discovery
- Clinical Stage
website: https://www.attovia.com/
---
